Nektar Therapeutics
We believe that Nektar Therapeutics (NKTR) is undervalued. We base this on the firm’s technological capability. Its current pipeline is filled with promising products. Today we learned that the U.S. FDA granted Nektar’s and Bristol-Myers Squibb’s . . .
This content is for paid subscribers.
Today’s Highlights
August 1, 2019
